Delivering Transformative Medicines
Exopharm (ASX:EX1) is a leader in exosome technology and holds a portfolio of intellectual property and know-how related to exosomes and the manufacture of exosomes.
Using exosomes to deliver transformative medicines
- Enabling Biopharma companies to deliver new and existing drug candidates in novel ways
- Designing and evaluating entirely new exosome medicines
Exosomes are nano-sized particles produced by most animal cells to exchange materials and genetic instructions and co-ordinate cellular activities in our bodies. For some medicines, exosomes are an alternative and superior means for delivery inside the body.
Exopharm has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.
Exopharm’s LEAP manufacturing technology provides access to large quantities of high-purity exosomes for research and clinical uses.
Exopharm is a publicly traded company on the Australian Securities Exchange under code ASX:EX1.
Visit our Resources section for ASX announcements, investor information, news and articles.
Under News and Articles, access more information about exosomes, news, whitepapers and opinion articles. Also find links to past talks and webinars.